GJ-CSPC@EC2612A

Anritumab Injection Approved for Marketing by NMPA in Collaboration between CSPC and Concert Pharmaceuticals

CICC and China International Securities Reiterate Buy Rating on CSPC, Set Target Prices at 12.00 and 13.05 HKD

DAH CHAI HIN DOWNGRADES CSPC PHARMACEUTICAL TO SELL ON POOR Q1 RESULTS

Morgan Stanley Maintains Overweight on CSPC Group, Raises Target Price to HKD 11 After Q1 Results

CSPC Pharmaceutical Group Releases 2026 Q1 Report: Revenue and Net Profit Fall, Stock Price Drops Over 5%

UBS Maintains Buy Rating on CSPC, Anticipates $1.2B AstraZeneca Payment in Q2 2026

CSPC Group Q1 Revenue 6.47 Billion, R&D Spend 1.4 Billion

CSPC PHARMA released FY2026 Q1 earnings on May 27 Pre-Market (BJT), actual revenue HKD 7.33 B (forecast HKD 7.533 B), actual EPS HKD 0.0854 (forecast HKD 0.1303)

CSPC's Lansoprazole Enteric-coated Capsules Obtain NMPA Registration Approval

Huitianfu Fund reduces 9.824 million shares of CSPC Pharmaceutical on May 19, raising approx 73.22 million HKD

CSPC Pharma's Enric (Ustekinumab Injection) Approved for Psoriasis Treatment

Sinopharm New World Subsidiary Approved to Market Ustekinumab Injection

UBS Upgrades CSPC Pharmaceutical to Buy, Cites AI Drug R&D and Valuation Potential

CSPC PHARMA FY2026 Q1 Earnings Release on May 27 Pre-Market (BJT), Forecast Revenue HKD 7.905 B, EPS HKD 0.102

CSPC's SYH2095 receives clinical trial approval and FDA clearance, trials set to begin in April 2026

Jade Pharmaceutical's SYS6010 Enters Phase 3 Clinical Trials for Esophageal Squamous Cell Carcinoma

Jiayi Group's BD Project MAT2A Inhibitor Downgraded by BeiGene

Jade Pharmaceutical Group Develops Online Infrared Spectroscopy Technology for Oligonucleotide Solid-Phase Deprotection Process

Huitianfu Fund Management Co. Increased Its Holdings in CSPC Group

Ji Pharmacy Group's Amphotericin B Liposome Injection Approved in the EU

JOLIMARK

TIMES UNI GP

APEX ACE HLDG

VPOWER GROUP

GW TIANDI

FUJING HOLDINGS

TEAMWAY INTL GP

SFSY NEW MAT

FDB HOLDINGS

KEEN OCEAN

01093

513120

520500

159570

159506

512010

510660

562050

CSPC Pharmaceutical Group missed Q1 earnings estimates by 33%, causing a 2.5% share drop. However, analysts have upgraded 2026 forecasts, projecting revenue growth of 24% to CN¥31.5b and EPS surge of 154% to CN¥0.72. Despite these positive sentiment shifts and expectations of faster growth than the industry, the consensus price target remains unchanged at HK$11.46, reflecting divergent analyst views.

Simplywall

CSPC PHARMA

GF CSI HK Innovative Drugs Industry ETF(QDII)

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

Guotai CSI Bio-medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

CSPC Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

CSPC Pharmaceutical (1093) received a US$1.2 billion upfront payment from AstraZeneca, disclosed May 29, 2026, tied to their collaboration agreement. 1CSPC Pharmaceutical Group (1093) got NMPA approval to commercially sell Ennituo (Anbenitamab Injection) in China, enabling market distribution and sales of the branded injection. 2

TradingView

AstraZeneca

AstraZeneca PLC

VG Health

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Direxion S&P Biotech Bear 3X

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

iShares Biotechnology ETF

Health Care Select Sector SPDR

SPDR S&P Biotech

VanEck Biotech ETF

ALPS Medical Breakthrough

Proshares UltraShort Nasdaq Biotech

Key facts: CSPC nets $1.2B from AstraZeneca; Ennituo cleared in China

CSPC Pharma rose 8.05% to HK$7.49 with a turnover of HK$925.21M. Q1 net profit fell 41.8% to RMB 860M.

HK Stock Market Update

CSPC Pharma Surges Over 8% Amid Mixed Analyst Ratings

CICC has reaffirmed its Buy rating for CSPC Pharmaceutical Group (CHJTF) with a price target of HK$12.00, while the stock closed at HK$6.96. The average analyst consensus rating is Moderate Buy with a target of HK$10.42, indicating a potential 49.70% upside. CMB International Securities also maintains a Buy rating with a target of HK$13.05.

Tip Ranks

CICC

CICC Sticks to Their Buy Rating for CSPC Pharmaceutical Group (CHJTF)

CSPC Pharmaceutical Group's shareholders approved all resolutions at the AGM on May 28, 2026, including the 2025 audited financial statements and a final dividend of HK15 cents per share. The re-election of directors and the reappointment of Deloitte as auditor were also supported, despite some opposition. A special resolution to adopt new Articles of Association was passed, reflecting governance updates. The stock has a Buy rating with a target price of HK$13.05.

CSPC Pharmaceutical Wins Shareholder Backing for All AGM Resolutions

UBS reported that CSPC PHARMA's 1Q26 net profit fell 41.8% YoY to RMB860 million, missing forecasts, while revenue was RMB6.5 billion, down 7.8% YoY but exceeding expectations. The bank maintains a Buy rating with a target price of HKD10.9, citing strong drug sales growth and limited impact from recent policy changes. The USD1.2 billion payment from AstraZeneca is expected in 2Q26.

AASTOCKS News

UBS Group AG

UBS: CSPC PHARMA  1Q26 Net Profit Misses; Revenue Beats; Rated Buy

CSPC Pharmaceutical Group's shares dropped over 10% in afternoon trading after reporting a 41.8% decline in Q1 net profit compared to last year. The company is listed on the Hong Kong Stock Exchange under ticker.

CoinLive

STOCKS | CSPC Pharmaceutical Group Shares Drop Over 10% as Q1 Net Profit Falls 41.8%

CSPC Pharmaceutical Group reported a 7.8% decline in Q1 2026 revenue to RMB6.47 billion, with profit attributable to shareholders dropping 41.8% to RMB860 million, primarily due to a significant decrease in licence fee income. Finished drug sales grew 6.2%, but overall revenue fell 5%. Analysts maintain a Buy rating on the stock with a price target of HK$13.05.

CSPC Pharmaceutical Profit Slumps on Sharp Drop in Licence Fee Income

CSPC PHARMA reported a 40.3% YoY decline in basic profit for 1Q26, totaling RMB842 million. Revenue fell 7.8% YoY to RMB6.465 billion, with net profit down 41.8% to RMB860 million. The finished drug business generated RMB5.224 billion, a 5% decrease YoY, largely due to reduced licensing fee income. R&D expenses rose 7.7% YoY to RMB1.403 billion, representing 26.8% of finished drug revenue.

CSPC PHARMA  1Q26 Basic Profit Falls 40.3% YoY to RMB842 million

GJ-CSPC@EC2612A(29612.HK)